Portfoliotracker

Immix Biopharma, Inc.

IMMX · NASDAQCM · Healthcare Biotechnology 22/100 E

7,480 $
▼ −0,360 (−4,59 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:52
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score22 / 100 Market cap554 mil. $ P/E– Forward P/E-7,5 P/S– P/B1,7 EV/EBITDA– Dividend yield– FCF yield-8,16 % EPS-0,79 $ Net margin0,0 % Return on equity-26,9 % Beta0,29 Debt / equity0,00
52-week range 3,78 to 15,10
3-month average volume1,5 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Employees
21
Country
United States
Fiscal year end
31. 12.
Data since
16. 12. 2021

Explore further

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account